Scarica l'app Stockscreener
0.80
0.88%
0.007
Dopo l'orario di chiusura:
.81
0.01
+1.25%
Precedente Chiudi:
$0.793
Aprire:
$0.8006
Volume 24 ore:
131.58K
Relative Volume:
0.28
Capitalizzazione di mercato:
$56.79M
Reddito:
-
Utile/perdita netta:
$-46.12M
Rapporto P/E:
-0.9257
EPS:
-0.8642
Flusso di cassa netto:
$-41.02M
1 W Prestazione:
+3.91%
1M Prestazione:
-56.76%
6M Prestazione:
-68.13%
1 anno Prestazione:
-52.10%
Intervallo 1D:
$0.7745
$0.8178
Intervallo di 1 settimana:
$0.7599
$0.8318
Portata 52W:
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
Confronta IFRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.80 | 56.79M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-02-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-10-28 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-06 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-04-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-05 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-01-29 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-10 | Iniziato | Credit Suisse | Outperform |
| 2018-07-13 | Iniziato | BMO Capital Markets | Outperform |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-28 | Iniziato | SunTrust | Buy |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Inflarx N V Borsa (IFRX) Ultime notizie
Analyzing InflaRx (NASDAQ:IFRX) and Inhibitor Therapeutics (OTCMKTS:INTI) - Defense World
Brokers Offer Predictions for InflaRx FY2026 Earnings - Defense World
InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events - The Globe and Mail
InflaRx (NASDAQ:IFRX) Short Interest Update - Defense World
InflaRx (NASDAQ:IFRX) Price Target Cut to $3.00 by Analysts at Oppenheimer - Defense World
InflaRx stock rating cut, price target slashed to $2 by Raymond James - Investing.com Nigeria
InflaRx (IFRX) Maintains Outperform Rating, Price Target Adjusted | IFRX Stock News - GuruFocus
IFRX Price Target Cut as Phase 3 Trial Halts | IFRX Stock News - GuruFocus
Oppenheimer Adjusts Price Target on InflaRx N.V to $3 From $6, Maintains Outperform Rating - marketscreener.com
Raymond James Downgrades InflaRx to Outperform From Strong Buy, Price Target is $13 - marketscreener.com
Guggenheim maintains $10 target on Inflarx despite study halt - Investing.com Australia
InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Sto - GuruFocus
InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Stock News - GuruFocus
InflaRx downgraded to Outperform from Strong Buy at Raymond James - TipRanks
Top Midday Decliners - marketscreener.com
Crude Oil Gains 2%; Macy's Lowers Earnings Forecast - Benzinga
Guggenheim maintains $10 target on Inflarx despite study halt By Investing.com - Investing.com Nigeria
InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease - Benzinga
PG rating: Inflarx review declares phase III bomb - BioWorld MedTech
InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial - insights.citeline.com
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
InflaRx (IFRX) Halts Key Drug Trials, Refocuses Strategy - GuruFocus
InflaRx Halts Vilobelimab Phase 3 Trial for Pyoderma Gangrenosum - TipRanks
InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell - marketscreener.com
InflaRx stock plunges on plans to drop lead asset (IFRX:NASDAQ) - Seeking Alpha
InflaRx (IFRX) Halts Phase 3 Trial for Vilobelimab, Shifts Focus - GuruFocus
InflaRx to discontinue vilobelimab indication following IDMC recommendation - TipRanks
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum - GlobeNewswire
Clinical Trial Setback: InflaRx Discontinues Key Drug Program After Phase 3 Futility Results - Stock Titan
InflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust Corp - Defense World
InflaRx to Participate in Upcoming Investor Conferences - The Manila Times
InflaRx Sets Ambitious Investor Conference Tour: Jefferies, Oppenheimer, and Leerink Partners Ahead - Stock Titan
Cubist Systematic Strategies LLC Makes New Investment in InflaRx (NASDAQ:IFRX) - Defense World
Schonfeld Strategic Advisors LLC Sells 7,756 Shares of InflaRx (NASDAQ:IFRX) - Defense World
Certain Pre-Funded Warrants of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Certain Options of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Raymond James maintains Strong Buy on Inflarx stock, $13 target By Investing.com - Investing.com Nigeria
Raymond James maintains Strong Buy on Inflarx stock, $13 target - Investing.com
FY2025 EPS Estimates for InflaRx Raised by Cantor Fitzgerald - Defense World
Q2 Earnings Forecast for InflaRx Issued By Leerink Partnrs - Defense World
InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024) - Yahoo Finance
Oppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform Recommendation - Nasdaq
This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Benzinga
InflaRx N.V. Reports Q1 2025 Financial Results - TipRanks
InflaRx reports Q1 EPS (EUR 0.13) vs (EUR 0.17) last year - TipRanks
InflaRx Reports Q1 2025 Financial Results with Reduced Losses - TipRanks
InflaRx (IFRX) Awaits Key Milestones in Drug Development | IFRX Stock News - GuruFocus
InflaRx N.V. Announces Progress in Toxicology Studies for INF904 and Upcoming Phase 3 Interim Analysis of Vilobelimab - Nasdaq
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
InflaRx NV expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Inflarx N V Azioni (IFRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):